Published 5 days ago • loading... • Updated 5 days ago

CARsgen Announces Data of Allogeneic BCMA CAR-T Cell Therapy CT0596 for Relapsed/Refractory Multiple Myeloma at the 2025 ASH Annual Meeting

Presenting at ASH, CARsgen reported preliminary favorable tolerability and encouraging efficacy for CT0596 earlier this year, according to the poster shown at the 67th American Society of Hematology Annual Meeting.
The dose‑escalation trial NCT06718270 enrolled 8 patients, all evaluable as of Aug. 31, 2025, with CT0596 dosed at 1.5×10x and varied lymphodepletion regimens.
Response and MRD data reveal six patients achieving PR or better, including 3 CR/sCR, and six full-dose patients achieved MRD-negativity at Week 4.
CT0596 showed a manageable safety profile, with no ICANS or GVHD reported and no dose‑limiting toxicities or deaths; CARsgen plans an Investigational New Drug submission in the second half of 2025 and a Phase 1b registrational study in 2026.
CARsgen's capabilities position the company to advance CT0596 through investigator‑initiated trials for relapsed/refractory multiple myeloma and plasma cell leukemia, targeting plasma cell malignancies and autoimmune diseases mediated by autoreactive plasma cells with its THANK‑u Plus platform.

Insights by Ground AI

53 Articles

Bennington Banner

+52 Reposted by 52 other sources

Center

CARsgen Announces Data of Allogeneic BCMA CAR-T Cell Therapy CT0596 for Relapsed/Refractory Multiple Myeloma at the 2025 ASH Annual Meeting

SHANGHAI, Dec. 7, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announced that clinical data from its allogeneic BCMA-targeted CAR T-cell product candidate, CT0596, for the treatment of relapsed/refractory…

5 days ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year